# Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

> **NCT07145450** · PHASE1,PHASE2 · RECRUITING · sponsor: **Anocca AB** · enrollment: 96 (estimated)

## Conditions studied

- PDAC

## Interventions

- **BIOLOGICAL:** ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)
- **BIOLOGICAL:** ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)
- **BIOLOGICAL:** ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles)

## Key facts

- **NCT ID:** NCT07145450
- **Lead sponsor:** Anocca AB
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-03
- **Primary completion:** 2030-04-02
- **Final completion:** 2030-07-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07145450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07145450, "Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT07145450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*